<DOC>
	<DOCNO>NCT02792699</DOCNO>
	<brief_summary>This trial design determine effect human body investigational medicine , ABP 798 , effect body investigational medicine give , comparable see licensed medicine , rituximab , patient moderate severe RA . This study assess investigational medicine safe effective treat moderate severe RA compare license medicine .</brief_summary>
	<brief_title>Study Assess ABP798 Safe &amp; Effective Treating Moderate Severe Rheumatoid Arthritis Compared Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Men woman ≥ 18 ≤ 80 year old Subjects must diagnose Rheumatoid Arthritis least 6 month baseline Active RA define ≥ 6 swollen joint ≥ 6 tender joint screen baseline least one follow screening : erythrocyte sedimentation rate ( ESR ) ≥ 28 mm/hr serum Creactive protein ( CRP ) &gt; 1.0 mg/dL Subjects must take methotrexate ( MTX ) ≥ 12 consecutive week stable dose MTX 7.5 25 mg/week ≥ 8 week prior receive investigational product ( IP ) , willing remain stable dose throughout study Subject know history active tuberculosis Class IV RA , Felty 's syndrome history prosthetic native joint infection Major chronic inflammatory disease connective tissue disease RA , exception secondary Sjögren 's syndrome Use commercially available investigational biologic therapy RA follow : anakinra , etanercept within 1 month prior first dose IP infliximab , abatacept , tocilizumab , golimumab , certolizumab within 3 month prior first dose IP experimental commercially available biologic therapy RA within 3 month 5 halflives ( whichever longer ) prior first dose IP Previous receipt rituximab biosimilar rituximab Other Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>